YOLFTbeta
Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc. Common Stock

ZBIO · NASDAQ · Healthcare / Biotechnology

28.01USD+0.37 (+1.34%)

Price History

Full chart

Market Stats

Previous Close27.64
Open27.58
Day Range26.89 – 28.18
52-Week Range13.50 – 44.60
Volume304.82K
Market Cap1.74B
P/E (TTM)0.00
Forward P/E0.00
EPS-9.63
Dividend Yield0.00%
Beta-1.02
50-Day Avg31.46
200-Day Avg25.43

About

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Leon Oliver Moulder Jr., M.B.A.
  • Employees167
  • Headquarters852 Winter Street, Waltham, MA, United States, 02451, USA
  • Websitehttps://zenasbio.com

Leadership

  • Mr. Leon Oliver Moulder Jr., M.B.A.Founder, CEO & Chairman · b. 1957
  • Mr. Joseph L. FarmerCOO & President · b. 1972
  • Dr. Lisa von Moltke M.D.Head of Research & Development and Chief Medical Officer · b. 1959
  • Dr. Heinrich Schlieker Ph.D.Chief Technical Officer
  • Dr. Haley Laken Ph.D.Chief Scientific Officer
  • Ms. Caroline ChevalierChief Administrative Officer
  • Mr. Jeffrey HeldChief Legal Officer · b. 1969

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue050.00M5.00M10.00M
Growth (%)---90.00%+100.00%
Cost of Revenue61.69M113.00K139.14M56.00K
Gross Profit-61.69M50.00M-134.14M10.00M
Gross Margin-100.00%-2682.78%100.00%
Operating Expense14.51M87.15M29.75M221.38M
Operating Income-76.20M-37.15M-163.89M-211.38M
Operating Margin--74.29%-3277.76%-2113.85%
EBITDA-75.12M-27.03M-156.42M-370.43M
EBITDA Margin--54.07%-3128.44%-3704.33%
Net Income-119.28M-37.12M-156.99M-377.74M
Net Income Margin--74.25%-3139.76%-3777.37%
R&D62.69M60.03M139.14M168.06M
R&D as % of Total Revenue-120.07%2782.78%1680.63%
Interest Expense--07.33M
Interest Expense % of Total Revenue--0.00%73.27%

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets74.58M68.18M369.97M383.64M
Total Liabilities266.87M293.90M57.51M141.50M
Total Equity-192.29M-225.72M312.46M242.14M
Cash67.21M56.86M319.74M110.64M
Total Debt1.53M21.11M1.00M79.96M
Net Debt-65.68M-35.74M-318.74M-30.68M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-65.65M-30.53M-119.67M-172.33M
Investing Cash Flow-2.20M-17.00K-30.55M-251.89M
Financing Cash Flow59.39M20.12M412.96M215.28M
Capital Expenditure2.20M17.00K131.00K18.00K
Free Cash Flow-67.85M-30.55M-119.81M-172.35M
FCF to OCF103.35%100.06%100.11%100.01%

Earnings

Report DateAug 22, 2024Nov 12, 2024Feb 26, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 16, 2026May 13, 2026Aug 13, 2026
EPS Estimate-1.24-9.30-1.02-1.15-1.06-0.85-1.19-1.54-0.89
EPS Actual-2.79-5.02-1.26-0.80-1.25-1.22-1.39-1.46-1.77
Surprise-125.00%46.02%-23.69%30.43%-17.92%-43.53%-16.81%5.19%-98.88%
TimingAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap1.74B
Enterprise Value1.59B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1744.13
Price / Book7.82
EPS-9.63
Book Value3.90
Revenue (TTM)1.00M
Gross Profit (TTM)-212.47M
EBITDA-273.87M
Profit Margin0.00%
Operating Margin-7765.90%
Return on Equity-199.04%
Return on Assets-34.42%
Shares Outstanding65.18M
Shares Float45.02M
Beta-1.02
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 47.00
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
100.90%
Insiders
19.75%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    9.08M13.93%
  • SR ONE CAPITAL MANAGEMENT, LP
    5.04M7.73%
  • NEA Management Company, LLC
    4.02M6.17%
  • Enavate Sciences GP, LLC
    3.92M6.01%
  • Federated Hermes Inc
    3.12M4.78%
  • Polar Capital Holdings PLC
    2.55M3.91%
  • Capital Research & Mgmt Co - Division 3
    2.50M3.84%
  • Fairmount Funds Management LLC
    2.36M3.62%
  • BlackRock Inc
    2.04M3.13%
  • NVP Associates LLC
    1.84M2.82%
  • Wellington Management Company LLP
    1.59M2.45%
  • State Street Corp
    1.47M2.26%
  • Vanguard Capital Management, LLC
    1.25M1.91%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    1.14M1.74%

Top Fund Holders

  • American Funds SMALLCAP World A
    2.43M3.73%
  • Polar Capital Biotech S Inc
    2.29M3.51%
  • Federated Hermes Kaufmann R
    1.82M2.80%
  • State Street® SPDR® S&P® Biotech ETF
    1.42M2.19%
  • Federated Hermes Kaufmann Small Cap A
    1.25M1.92%
  • Fidelity Small Cap Growth
    1.15M1.76%